Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Cushing's Disease (CD), the leading cause of endogenous Cushing's Syndrome (CS), results from the persistent overproduction of ACTH by a pituitary corticotroph adenoma. CD predominantly affects females, with a female-to-male ratio of 4-5:1, except in prepubertal patients, where males are more commonly affected. The peak age of onset occurs between 25 and 40 years. CD symptoms include typical CS features like central obesity, facial rounding, hypercatabolism signs, skin hyperpigmentation, and, in some cases, corticotroph macro-adenoma, neurological complications. Cushing's syndrome can present with varying signs and symptoms. Prolonged exposure to elevated cortisol levels leads to evident manifestations such as weight gain, thin extremities, a rounded face, fat accumulation around the neck, a fatty hump between the shoulders, easy bruising, wide purple stretch marks, mainly on the abdomen, breasts, hips, and under the arms, and muscle weakness. The exact pathogenesis of pituitary tumors remains largely unknown. Most pituitary adenomas are sporadic, although a small percentage (<5%) occur within familial syndromes like multiple endocrine neoplasia type 1 (MEN 1), caused by MEN1 gene mutations (11q13), familial isolated pituitary adenomas (FIPA), where 15% of patients have AIP gene mutations (11q13-32), and the recently described multiple endocrine neoplasia type 4 (MEN 4), linked to CDKN1B gene mutations. Endogenous Cushing's syndrome is traditionally classified as ACTH-dependent or ACTH-independent. ACTH-dependent cases account for 80%-85% of all instances. Among these, approximately 75%-80% stem from pituitary adenomas (Cushing's Disease or CD), 15%-20% from nonpituitary tumors (ectopic ACTH syndrome or EAS), and less than 1% from corticotropin-releasing hormone (CRH)-producing tumors. Most pituitary tumors arise sporadically, originating from a single mutated cell. Surgical removal of the source of excess glucocorticoids, whether a pituitary adenoma, nonpituitary ACTH-secreting tumor, or adrenal tumor(s), is the primary treatment for all forms of Cushing's syndrome. Transsphenoidal surgery yields an initial remission rate of 60%-80% (less than 15% in macroadenomas) with a relapse rate of up to 20% within a decade.

  • In the United States, the reported incidence of Cushing's Disease ranges from 6.2 to 7.6 cases per million person-years.


Thelansis’s “Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Cushing’s Syndrome (CS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cushing’s Syndrome (CS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more